

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH **DYSPEPSIA, PEPTIC ULCER DISEASE, GASTROESOPHAGEAL REFLUX DISEASE AND H. PYLORI ERADICATION**

1. **Gastro-oesophageal reflux disease.** In: *BMJ Best Practice*. 07 Feb 2017.
2. **Assessment of dyspepsia.** In: *BMJ Best Practice*. 09 Jan 2017.
3. **Peptic Ulcer Disease.** In: *BMJ Best Practice*. 11 Apr 2017.
4. AA Pharma Inc: **Elavil (amitriptyline).** In: *CA Product Monograph*. Vaughan, ON; 2010.
5. AA Pharma Inc: **Misoprostol.** In: *CA Product Monograph*. Toronto, Ontario; 2010.
6. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L *et al*: **ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.** *Journal of the American College of Cardiology* 2010, **56**(24):2051-2066.
7. Agrawal NM, Van Kerckhove HE, Erhardt LJ, Geis GS: **Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study.** *Digestive diseases and sciences* 1995, **40**(5):1125-1131.
8. Allergan Inc: **Carafate (sucralfate).** In: *US Product Monograph*. Madison, NJ; 2018.
9. Allescher HD, Bockenhoff A, Knapp G, Wienbeck M, Hartung J: **Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies.** *Scandinavian journal of gastroenterology* 2001, **36**(9):934-941.
10. American Geriatrics Society Beers Criteria Update Expert Panel: **American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.** *Journal of the American Geriatrics Society* 2015, **63**(11):2227-2246.
11. Ang TL, Fock KM, Teo EK, Chan YH, Ng TM, Chua TS, Tan JY: **Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.** *Journal of gastroenterology* 2006, **41**(7):647-653.
12. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI: **Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or**

- without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.** *The American journal of gastroenterology* 2014, **109**(6):811-819.
13. ANI Pharmaceuticals Inc: **Reglan (metoclopramide hydrochloride)**. In: *US Product Monograph*. Baudette, MN; 2017.
 14. Apotex Inc: **Apo-Ranitidine**. In: *CA Product Monograph*. Toronto, ON; 2016.
 15. Apotex Inc: **Apo-amitriptyline**. In: *CA Product Monograph*. Toronto, ON; 2019.
 16. Aptalis Pharma Canada Inc: **Sulcrate (sucralfate)** In: *CA Product Monograph*. Mont-St-Hilaire, QC; 2013.
 17. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, Hollingworth R, Hunt RH, Kahrilas PJ, Mayrand S *et al*: **Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004.** *Canadian journal of gastroenterology = Journal canadien de gastroenterologie* 2005, **19**(1):15-35.
 18. Armstrong D, Marchetti N: **Pharmacist-specific guidelines for the medical management of GERD in adults.** *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada* 2008, **141**(1 suppl):S10-S15. e13.
 19. Armstrong D, Nakhla N: **Non-prescription proton-pump inhibitors for self-treating frequent heartburn: the role of the Canadian pharmacist.** *Pharm Pract (Granada)* 2016, **14**(4):868.
 20. Asge Standards of Practice Committee, Banerjee S, Cash BD, Dominitz JA, Baron TH, Anderson MA, Ben-Menachem T, Fisher L, Fukami N, Harrison ME *et al*: **The role of endoscopy in the management of patients with peptic ulcer disease.** *Gastrointest Endosc* 2010, **71**(4):663-668.
 21. Asge Standards of Practice Committee, Muthusamy VR, Lightdale JR, Acosta RD, Chandrasekhara V, Chathadi KV, Eloubeidi MA, Fanelli RD, Fonkalsrud L, Faulx AL *et al*: **The role of endoscopy in the management of GERD.** *Gastrointest Endosc* 2015, **81**(6):1305-1310.
 22. AstraZeneca Canada Inc: **Nexium (esomeprazole)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
 23. AstraZeneca Canada Inc: **Losec (omeprazole)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
 24. AstraZeneca Pharmaceuticals LP: **Nexium (esomeprazole)**. In: *US Product Monograph*. Wilmington, DE; 2018.
 25. Barkun AN, Crott R, Fallone CA, Kennedy WA, Lachaine J, Levinton C, Armstrong D, Chiba N, Thomson A, Veldhuyzen van Zanten S *et al*: **A one-year economic evaluation**

- of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care.** *Canadian journal of gastroenterology = Journal canadien de gastroenterologie* 2010, **24**(8):489-498.
26. Bayer Inc: **Phillips' Milk of Magnesia.** In. Whippany, NJ; 2016.
 27. Baysal B, Senturk H, Masri O, Tozlu M, Kayar Y, Arabaci E, Uysal O, Bugdaci MS, Ince AT: **Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients.** *The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology* 2015, **26**(1):6-14.
 28. BC Renal Agency: **Over-the-Counter (non-prescription) medications and your kidneys.** In. Edited by Agency BR. St. Pauls Hospital: BC Provincial Renal Agency; 2014.
 29. Bekhti A, Rutgeerts L: **Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying.** *Postgraduate medical journal* 1979, **55**:30-32.
 30. BGP Pharma ULC: **Prevacid (lansoprazole).** In: *CA Product Monograph.* Etobicoke, ON; 2017.
 31. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA *et al*: **ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.** *Journal of the American College of Cardiology* 2008, **52**(18):1502-1517.
 32. Bianchi Porro G, Lazzaroni M, Imbesi V, Montrone F, Santagada T: **Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study.** *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver* 2000, **32**(3):201-208.
 33. Blum AL, Bethge H, Bode JC, Domschke W, Feurle G, Hackenberg K, Hammer B, Huttemann W, Jung M, Kachel G *et al*: **Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study.** *Gut* 1990, **31**(7):825-830.
 34. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR: **Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.** *Gut* 2000, **47**(4):473-480.
 35. Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, Geis GS, Fort JG: **Diclofenac/misoprostol compared with diclofenac in the treatment of**

- osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.** *The Journal of rheumatology* 1998, **25**(8):1602-1611.
36. Body C, Christie JA: **Gastrointestinal Diseases in Pregnancy: Nausea, Vomiting, Hyperemesis Gravidarum, Gastroesophageal Reflux Disease, Constipation, and Diarrhea.** *Gastroenterology clinics of North America* 2016, **45**(2):267-283.
 37. Bolten W, Gomes JA, Stead H, Geis GS: **The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis.** *British journal of rheumatology* 1992, **31**(11):753-758.
 38. Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE: **Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study.** *Alimentary pharmacology & therapeutics* 2011, **34**(6):638-648.
 39. Briggs GG, Freeman RK, Towers CV, Forinash AB: **Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk**, Eleventh edition. edn. Philadelphia, PA: Wolters Kluwer; 2017.
 40. British Columbia Guidelines & Protocols Advisory Committee: **Dyspepsia with or without Helicobacter pylori infection - Clinical Approach in Adults.** In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2009.
 41. British Columbia Guidelines & Protocols Advisory Committee: **Gastroesophageal Reflux Disease - Clinical Approach in Adults.** In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2009.
 42. Canadian Pharmacists Association: **Misoprostol [CPhA monograph].** In: *RxTx*. Ottawa, ON; 2012.
 43. Canadian Pharmacists Association: **Histamine H2-receptor Antagonists [CPhA monograph].** In: *RxTx*. Ottawa, ON; 2013.
 44. Canadian Pharmacists Association: **Metoclopramide [CPhA Monograph].** In: *RxTx*. Ottawa, ON; 2015.
 45. Canadian Pharmacists Association: **Domperidone [CPhA Monograph].** In: *RxTx*. Ottawa, ON; 2015.
 46. Canadian Pharmacists Association: **Tricyclic Antidepressants [CPhA Monograph].** In: *RxTx*. Ottawa, ON; 2016.
 47. Canadian Pharmacists Association: **Magnesium Salts [CPhA Monograph].** In: *TxTx*. Ottawa, ON; 2017.

48. Canadian Pharmacists Association: **Antacid, Antiflatulent and Antireflux [CPhA monograph]**. In: *RxTx*. 2019.
49. Cange L, Johnsson E, Rydholm H, Lehmann A, Finizia C, Lundell L, Ruth M: **Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease**. *Alimentary pharmacology & therapeutics* 2002, **16**(5):869-873.
50. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE *et al*: **Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)**. *Genetics in medicine : official journal of the American College of Medical Genetics* 2017, **19**(2):215-223.
51. Champion MC: **Prokinetic therapy in gastroesophageal reflux disease**. *Canadian journal of gastroenterology = Journal canadien de gastroenterologie* 1997, **11 Suppl B**:55b-65b.
52. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, Hui AJ, Leung VK, Lee VW, Lai LH *et al*: **Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial**. *Lancet (London, England)* 2007, **369**(9573):1621-1626.
53. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ: **Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users**. *Gastroenterology* 2013, **144**(3):528-535.
54. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: **Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis**. *Gastroenterology* 1997, **112**(6):1798-1810.
55. Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E: **Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial**. *BMJ* 2002, **324**(7344):1012-1016.
56. Corazza GR, Biagi F, Albano O, Bianchi Porro G, Cheli R, Mazzacca G, Miglio F, Naccarato R, Quaglino D, Surrenti C *et al*: **Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial**. *The Italian journal of gastroenterology* 1996, **28**(6):317-323.
57. Corley DA, Kubo A: **Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis**. *The American journal of gastroenterology* 2006, **101**(11):2619-2628.

58. Corley DA, Kubo A, Zhao W, Quesenberry C: **Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.** *Gastroenterology* 2010, **139**(1):93-101.
59. Covis Pharma: **Prilosec (omeprazole).** In: *US Product Monograph.* Zug, Switzerland; 2018.
60. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J: **An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2009, **7**(12):1314-1321.
61. de Abajo FJ, Rodriguez LA, Montero D: **Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.** *BMJ* 1999, **319**(7217):1106-1109.
62. Delaney BC, Qume M, Moayyedi P, Logan RF, Ford AC, Elliott C, McNulty C, Wilson S, Hobbs FD: **Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial).** *BMJ* 2008, **336**(7645):651-654.
63. Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Thota P, Sferra TJ, Hernandez AV: **Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2012, **10**(3):225-233.
64. Dewan B, Philipose N: **Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial.** *Gastroenterol Res Pract* 2011, **2011**:640685.
65. Di Mario F, Battaglia G, Leandro G, Grasso G, Vianello F, Vigneri S: **Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials.** *Digestive diseases and sciences* 1996, **41**(6):1108-1131.
66. Dobrilla G, Comberlato M, Steele A, Vallaperta P: **Drug Treatment of Functional Dyspepsia: A Meta-Analysis of Randomized Controlled Clinical Trials.** *Journal of Clinical Gastroenterology* 1989, **11**(2):169-177.
67. **Pharmacogenomics guidelines** [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
68. Dwyer JP, Jayasekera C, Nicoll A: **Analgesia for the cirrhotic patient: a literature review and recommendations.** *J Gastroenterol Hepatol* 2014, **29**(7):1356-1360.

69. Einarson A, Maltepe C, Boskovic R, Koren G: **Treatment of nausea and vomiting in pregnancy: an updated algorithm.** *Canadian family physician Medecin de famille canadien* 2007, **53**(12):2109-2111.
70. Eisai Inc: **Aciphex (rabeprazole).** In: *US Product Monograph.* Woodcliff Lake, NJ; 2018.
71. Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdal J: **Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.** *European journal of gastroenterology & hepatology* 1995, **7**(5):467-475.
72. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P *et al*: **The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.** *Gastroenterology* 2016, **151**(1):51-69.e14.
73. Fennerty MB, Finke KB, Kushner PR, Peura DA, Record L, Riley L, Ruoff GE, Simonson W, Wright WL: **Short- and long-term management of heartburn and other acid-related disorders: development of an algorithm for primary care providers.** *The Journal of family practice* 2009, **58**(7 Suppl Short):S1-12.
74. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, Teare GF, Ravani P, Ernst P, Dormuth CR: **Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis.** *Gut* 2014, **63**(4):552-558.
75. Filion KB: **Proton pump inhibitors and community acquired pneumonia.** *BMJ* 2016, **355**:i6041.
76. Ford AC, Moayyedi P: **Treatment of chronic gastro-oesophageal reflux disease.** *BMJ* 2009, **339**:b2481.
77. Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ: **Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis.** *Gut* 2017, **66**(3):411-420.
78. Frech EJ, Go MF: **Treatment and chemoprevention of NSAID-associated gastrointestinal complications.** *Ther Clin Risk Manag* 2009, **5**:65-73.
79. Freedberg DE, Kim LS, Yang YX: **The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.** *Gastroenterology* 2017, **152**(4):706-715.
80. Freston JW: **Review article: role of proton pump inhibitors in non-H. pylori-related ulcers.** *Alimentary pharmacology & therapeutics* 2001, **15** Suppl 2:2-5.

81. Fuchs KH, Babic B, Breithaupt W, Dallemagne B, Fingerhut A, Furnee E, Granderath F, Horvath P, Kardos P, Pointner R *et al*: **EAES recommendations for the management of gastroesophageal reflux disease**. *Surgical endoscopy* 2014, **28**(6):1753-1773.
82. Fumagalli I, Hammer B: **Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial**. *Scandinavian journal of gastroenterology* 1994, **29**(1):33-37.
83. Garbis H, Elefant E, Diav-Citrin O, Mastroiacovo P, Schaefer C, Vial T, Clementi M, Valti E, McElhatton P, Smorlesi C *et al*: **Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services**. *Reprod Toxicol* 2005, **19**(4):453-458.
84. Garg DC, Baltodano N, Jallad NS, Perez G, Oster JR, Eshelman FN, Weidler DJ: **Pharmacokinetics of ranitidine in patients with renal failure**. *Journal of clinical pharmacology* 1986, **26**(4):286-291.
85. Gawronska-Szklarz B, Wrzesniewska J, Starzynska T, Pawlik A, Safranow K, Ferenc K, Drozdziak M: **Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection**. *European journal of clinical pharmacology* 2005, **61**(5-6):375-379.
86. Gawronska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, Drozdziak M: **CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers**. *European journal of clinical pharmacology* 2012, **68**(9):1267-1274.
87. GD Searle LLC Division of Pfizer Inc: **Cytotec (misoprostol)**. In: *US Product Monograph*. NY, NY; 2018.
88. Gill SK, O'Brien L, Einarson TR, Koren G: **The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis**. *The American journal of gastroenterology* 2009, **104**(6):1541-1545; quiz 1540, 1546.
89. GlaxoSmithKline Inc: **Tums**. In: *US Product Information*. 2019.
90. GlaxoSmithKline LLC: **Zantac (ranitidine)**. In: *US Product Monograph*. Research Triangle Park, NC; 2018.
91. Goh KL, Boonyapisit S, Lai KH, Chang R, Kang JY, Lam SK: **Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: a randomized double-blind, placebo-controlled study**. *J Gastroenterol Hepatol* 1995, **10**(1):92-97.
92. Goldstein JL, Larson LR, Yamashita BD: **Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet**

- formulation of diclofenac/misoprostol.** *The American journal of managed care* 1998, **4(5):687-697.**
93. Gonvers JJ, Aenishänslin W, Backwinkel K, Bretholz A, Egger G, Feyerabend H, Fumagalli I, Güller R, Hammer B, Mattle WP: **Gastric ulcer: a double blind comparison of 800 mcg misoprostol versus 300 mg ranitidine.** *Hepatogastroenterology* 1987, **34(5):233-235.**
 94. Goves J, Oldring JK, Kerr D, Dallara RG, Roffe EJ, Powell JA, Taylor MD: **First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice.** *Alimentary pharmacology & therapeutics* 1998, **12(2):147-157.**
 95. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, Huang B: **Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.** *Archives of internal medicine* 2002, **162(2):169-175.**
 96. Grossi L, Spezzaferro M, Sacco LF, Marzio L: **Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study.** *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society* 2008, **20(7):760-766.**
 97. Gwee KA, Goh V, Lima G, Setia S: **Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits.** *Journal of pain research* 2018, **11:361-374.**
 98. Hampel H, Abraham NS, El-Serag HB: **Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications.** *Annals of internal medicine* 2005, **143(3):199-211.**
 99. Hashash JG, Abdul-Baki H, Azar C, Elhajj II, El Zahabi L, Chaar HF, Sharara AI: **Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia.** *Alimentary pharmacology & therapeutics* 2008, **27(11):1148-1155.**
 100. Hata M, Shiono M, Sekino H, Furukawa H, Sezai A, Iida M, Yoshitake I, Hattori T, Wakui S, Soeda M *et al*: **Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.** *Circulation journal : official journal of the Japanese Circulation Society* 2005, **69(3):331-334.**
 101. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND: **Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.** *The New England journal of medicine* 1998, **338(11):727-734.**

102. He Y, Chan EW, Man KK, Lau WC, Leung WK, Ho LM, Wong IC: **Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.** *Drug safety* 2014, **37**(9):711-721.
103. Hemstreet BA: **Use of sucralfate in renal failure.** *The Annals of pharmacotherapy* 2001, **35**(3):360-364.
104. Hentschel E, Schutze K, Weiss W, Rudiger E, Judmair G, Reichel W, Kerstan E, Horton J: **Effect of cimetidine treatment in the prevention of gastric ulcer relapse: a one year double blind multicentre study.** *Gut* 1983, **24**(9):853-856.
105. Herrerias-Gutierrez JM, Pardo L, Segu JL: **Sucralfate versus ranitidine in the treatment of gastric ulcer. Randomized clinical results in short-term and maintenance therapy.** *The American journal of medicine* 1989, **86**(6A):94-97.
106. Holtmann G, Gschossmann J, Karaus M, Fischer T, Becker B, Mayr P, Gerken G: **Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia.** *Alimentary pharmacology & therapeutics* 1999, **13**(11):1459-1465.
107. Hrdina PD, Lapierre YD, Koranyi EK: **Altered amitriptyline kinetics in a depressed patient with porto-caval anastomosis.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 1985, **30**(2):111-113.
108. Hudson N, Taha AS, Russell RI, Trye P, Cottrell J, Mann SG, Swanell AJ, Sturrock RD, Hawkey CJ: **Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.** *Gastroenterology* 1997, **112**(6):1817-1822.
109. Hunfeld NG, Touw DJ, Mathot RA, Mulder PG, RH VANS, Kuipers EJ, Kooiman JC, Geus WP: **A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.** *Alimentary pharmacology & therapeutics* 2010, **31**(1):150-159.
110. Hunt R, Quigley E, Abbas Z, Eliakim A, Emmanuel A, Goh KL, Guarner F, Katelaris P, Smout A, Umar M *et al*: **Coping with common gastrointestinal symptoms in the community: a global perspective on heartburn, constipation, bloating, and abdominal pain/discomfort May 2013.** *Journal of clinical gastroenterology* 2014, **48**(7):567-578.
111. Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S, Chen MH, Choi MG, Melo AC, Fock KM *et al*: **World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease.** *Journal of clinical gastroenterology* 2017, **51**(6):467-478.

112. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T: **Randomized open trial for comparison of proton pump inhibitors in triple therapy for *Helicobacter pylori* infection in relation to CYP2C19 genotype.** *J Gastroenterol Hepatol* 2002, **17**(7):748-753.
113. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, Swanson KM, Sonnenberg A: **Step-down management of gastroesophageal reflux disease.** *Gastroenterology* 2001, **121**(5):1095-1100.
114. Infirst Healthcare Inc: **Mylanta.** In: *US Product Information.* 2019.
115. Iwakiri R, Higuchi K, Kato M, Fujishiro M, Kinoshita Y, Watanabe T, Takeuchi T, Yamauchi M, Sanomura M, Nakagawa H *et al*: **Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.** *Alimentary pharmacology & therapeutics* 2014, **40**(7):780-795.
116. Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S *et al*: **Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.** *Journal of gastroenterology* 2016, **51**(8):751-767.
117. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN: **Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.** *The American journal of gastroenterology* 2012, **107**(7):1001-1010.
118. Janssen Inc: **Pariet (rabeprazole).** In: *CA Product Monograph.* Toronto, ON; 2018.
119. Jarupongprapa S, Ussavasodhi P, Katchamart W: **Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.** *Journal of gastroenterology* 2013, **48**(7):830-838.
120. Jensen B, Regier L, Downey S, Karlson P, Taylor J: **OTC (over-the-counter) products.** In: *RxFiles drug comparison charts.* Saskatoon, SK: Saskatoon Health Region; 2017.
121. Jones RH, Baxter G: **Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice.** *Alimentary pharmacology & therapeutics* 1997, **11**(3):541-546.
122. Jones R, Crouch SL: **Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.** *Alimentary pharmacology & therapeutics* 1999, **13**(3):413-419.
123. Kang JM, Kim N, Lee DH, Park YS, Kim JS, Chang IJ, Song IS, Jung HC: **Effect of the CYP2C19 polymorphism on the eradication rate of *Helicobacter pylori* infection by**

- 7-day triple therapy with regular proton pump inhibitor dosage.** *J Gastroenterol Hepatol* 2008, **23**(8 Pt 1):1287-1291.
124. Kaosombatwattana U, Pongprasobchai S, Limsrivilai J, Maneerattanaporn M, Leelakusolvong S, Tanwandee T: **Efficacy and safety of nortriptyline in functional dyspepsia in Asians: A randomized double-blind placebo-controlled trial.** *J Gastroenterol Hepatol* 2018, **33**(2):411-417.
125. Katz PO, Gerson LB, Vela MF: **Guidelines for the diagnosis and management of gastroesophageal reflux disease.** *The American journal of gastroenterology* 2013, **108**(3):308-328; quiz 329.
126. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J: **Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.** *Gut* 2003, **52**(10):1397-1402.
127. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdziak M: **Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.** *European journal of clinical pharmacology* 2006, **62**(10):877-880.
128. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK: **Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.** *The American journal of gastroenterology* 2012, **107**(7):1011-1019.
129. Labenz J, Malfertheiner P: **Treatment of uncomplicated reflux disease.** *World journal of gastroenterology* 2005, **11**(28):4291-4299.
130. Lacy BE, Talley NJ, Locke GR, 3rd, Bouras EP, DiBaise JK, El-Serag HB, Abraham BP, Howden CW, Moayyedi P, Prather C: **Review article: current treatment options and management of functional dyspepsia.** *Alimentary pharmacology & therapeutics* 2012, **36**(1):3-15.
131. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO *et al*: **Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.** *The New England journal of medicine* 2002, **346**(26):2033-2038.
132. Laine L, Schoenfeld P, Fennerty MB: **Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.** *Annals of internal medicine* 2001, **134**(5):361-369.
133. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bujanda L, Gomollon F, Forne M, Aleman S, Nicolas D, Feu F, Gonzalez-Perez A *et al*: **Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.** *The American journal of gastroenterology* 2007, **102**(3):507-515.

134. Lanas A, Chan FK: **Peptic ulcer disease.** *Lancet (London, England)* 2017.
135. Lanza F, Goff J, Silvers D, Winters J, Jhala N, Jennings D, Greski-Rose P: **Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.** *Digestive diseases and sciences* 1997, **42**(12):2529-2536.
136. Lanza FL, Chan FK, Quigley EM: **Guidelines for prevention of NSAID-related ulcer complications.** *The American journal of gastroenterology* 2009, **104**(3):728-738.
137. Larson JD, Patatanian E, Miner PB, Jr., Rayburn WF, Robinson MG: **Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy.** *Obstetrics and gynecology* 1997, **90**(1):83-87.
138. Law R, Maltepe C, Bozzo P, Einarson A: **Treatment of heartburn and acid reflux associated with nausea and vomiting during pregnancy.** *Canadian family physician Medecin de famille canadien* 2010, **56**(2):143-144.
139. Leung WK, Wu JC, Chan FK, Fung SS, Wong VW, Hui AJ, Hung LC, Sung JJ: **Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up.** *The American journal of gastroenterology* 2007, **102**(7):1483-1488.
140. Lewin van den Broek NT, Numans ME, Buskens E, Verheij TJ, de Wit NJ, Smout AJ: **A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.** *The British journal of general practice : the journal of the Royal College of General Practitioners* 2001, **51**(469):619-624.
141. Lexicomp: **Domperidone.** In: *Lexi-Drugs.* Hudson, Ohio: Wolters Kluwer Health; 2018.
142. Limsrivilai J, Charatcharoenwitthaya P, Pausawasdi N, Leelakusolvong S: **Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.** *The American journal of gastroenterology* 2016, **111**(2):217-224.
143. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R *et al*: **On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.** *Alimentary pharmacology & therapeutics* 1999, **13**(7):907-914.
144. Loke YK, Trivedi AN, Singh S: **Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs.** *Alimentary pharmacology & therapeutics* 2008, **27**(1):31-40.

145. Lu Y, Chen M, Huang Z, Tang C: **Antidepressants in the treatment of functional dyspepsia: A systematic review and meta-analysis.** *PloS one* 2016, **11**(6).
146. Luo JC, Huang KW, Leu HB, Chen LC, Hou MC, Li CP, Lu CL, Lin HC, Lee FY, Lee SD: **Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer.** *Alimentary pharmacology & therapeutics* 2011, **34**(5):519-525.
147. Mahadevan U: **Gastrointestinal medications in pregnancy.** *Best Pract Res Clin Gastroenterol* 2007, **21**(5):849-877.
148. Maity S, Choudhury S, Hazra A, Das AK: **Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia.** *Indian journal of pharmacology* 2014, **46**(5):498-502.
149. Manlucu J, Tonelli M, Ray JG, Papaioannou A, Youssef G, Thiessen-Philbrook HR, Holbrook A, Garg AX: **Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence.** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2005, **20**(11):2376-2384.
150. Marelli S, Pace F: **Rabeprazole for the treatment of acid-related disorders.** *Expert review of gastroenterology & hepatology* 2012, **6**(4):423-435.
151. Masclee GM, Valkhoff VE, van Soest EM, Schade R, Mazzaglia G, Molokhia M, Trifiro G, Goldstein JL, Hernandez-Diaz S, Kuipers EJ *et al*: **Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?** *Alimentary pharmacology & therapeutics* 2013, **38**(2):178-189.
152. Mason I, Millar LJ, Sheikh RR, Evans WM, Todd PL, Turbitt ML, Taylor MD: **The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected].** *Alimentary pharmacology & therapeutics* 1998, **12**(3):263-271.
153. McCormack J CB, Calissi P: **Dosage Adjustment in Renal Impairment.** In: *Therapeutics.* Ottawa, ON: Canadian Pharmacists Association; 2018.
154. McKenna F: **Efficacy and gastroduodenal safety of a fixed combination of diclofenac and misoprostol in the treatment of arthritis.** *British journal of rheumatology* 1995, **34 Suppl 1**:11-18.
155. Medscape LLC: **Aluminum hydroxide/magnesium hydroxide/simethicone (OTC).** In: *US Product Information.* New York, NY; 2019.

156. Meineche-Schmidt V, Talley N, Pap A, Kordecki H, Schmid V, Ohlsson L, Wahlqvist P, Wiklund I, Bolling-Sternevald E: **Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment: a multicentre 3-month follow-up study.** *Scandinavian journal of gastroenterology* 1999, **34**(6):566-574.
157. Meineche-Schmidt V: **Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption.** *The American journal of gastroenterology* 2004, **99**(6):1050-1058.
158. Melo Gomes JA, Roth SH, Zeeh J, Bruyn GA, Woods EM, Geis GS: **Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis.** *Annals of the rheumatic diseases* 1993, **52**(12):881-885.
159. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA: **Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia.** *The American journal of gastroenterology* 1998, **93**(2):160-165.
160. Miwa H: **Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia.** *Journal of gastroenterology* 2012, **47**(8):862-871.
161. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ: **The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis.** *Gastroenterology* 2004, **127**(5):1329-1337.
162. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C *et al*: **Eradication of Helicobacter pylori for non-ulcer dyspepsia.** *The Cochrane database of systematic reviews* 2006(2):Cd002096.
163. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D: **Pharmacological interventions for non-ulcer dyspepsia.** *The Cochrane database of systematic reviews* 2006(4):Cd001960.
164. Moayyedi P, Soo S, Deeks JJ, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C *et al*: **Eradication of Helicobacter pylori for non-ulcer dyspepsia.** *The Cochrane database of systematic reviews* 2011(2):Cd002096.
165. Moayyedi P, Shelly S, Deeks JJ, Delaney B, Innes M, Forman D: **Pharmacological interventions for non-ulcer dyspepsia.** *The Cochrane database of systematic reviews* 2011(2):Cd001960.
166. Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N: **ACG and CAG Clinical Guideline: Management of Dyspepsia.** *The American journal of gastroenterology* 2017, **112**(7):988-1013.

167. Morgan MH, Read AE: **Antidepressants and liver disease.** *Gut* 1972, **13**(9):697-701.
168. Muller P, Hotz J, Franz E, Simon B: **Ranitidine in the treatment of non-ulcer dyspepsia. A placebo-controlled study in the Federal Republic of Germany.** *Arzneimittel-Forschung* 1994, **44**(10):1130-1132.
169. Murphy EJ: **Acute pain management pharmacology for the patient with concurrent renal or hepatic disease.** *Anaesth Intensive Care* 2005, **33**(3):311-322.
170. Mylan Pharmaceuticals Inc: **Amitriptyline.** In: *US Product Monograph.* Morgantown, WV; 2016.
171. Mylan Pharmaceuticals Inc: **Nizatidine** In: *US Product Monograph.* Morgantown, WV; 2016.
172. Nagata N, Niikura R, Aoki T, Shimbo T, Kishida Y, Sekine K, Tanaka S, Okubo H, Watanabe K, Sakurai T *et al*: **Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy.** *Gastrointest Endosc* 2014, **80**(6):1124-1131.
173. National Institute for Health and Care Excellence: **Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management [NICE Guideline CG184].** In.; 2014.
174. National Institute for Health and Care Excellence: **Non-steroidal anti-inflammatory drugs [NICE Guideline KTT13].** 2015.
175. Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A *et al*: **Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.** *Gastroenterology* 2010, **138**(1):82-88.
176. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G: **Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.** *Digestive diseases and sciences* 2002, **47**(7):1526-1529.
177. Nova Scotia Health Authority Renal Program: **Over-the-Counter Medications & Chronic Kidney Disease.** In. Edited by Nova Scotia Health Authority; 2016.
178. Novack L, Kogan S, Gimpelevich L, Howell M, Borer A, Kelly CP, Leffler DA, Novack V: **Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias.** *PloS one* 2014, **9**(10):e110790.
179. Oh JH, Choi MG, Dong MS, Park JM, Paik CN, Cho YK, Jeong JJ, Lee IS, Kim SW, Han SW *et al*: **Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients.** *J Gastroenterol Hepatol* 2007, **22**(9):1429-1434.

180. Oka Y, Okamoto K, Kawashita N, Shirakuni Y, Takagi T: **Meta-analysis of the risk of upper gastrointestinal hemorrhage with combination therapy of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs.** *Biological & pharmaceutical bulletin* 2014, **37**(6):947-953.
181. Olmos M: **Lansoprazole vs. omeprazole in speed of duo-denal ulcer healing.** *Gut* 1997, **41**(Suppl. 3)::A97.
182. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P: **STOPP/START criteria for potentially inappropriate prescribing in older people: version 2.** *Age and Ageing* 2015, **44**(2):213-218.
183. Orr WC, Goodrich S, Wright S, Shepherd K, Mellow M: **The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial.** *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society* 2012, **24**(6):553-559, e253.
184. Pace F, Tonini M, Pallotta S, Molteni P, Porro GB: **Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'.** *Alimentary pharmacology & therapeutics* 2007, **26**(2):195-204.
185. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH: **The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.** *The American journal of gastroenterology* 2006, **101**(7):1467-1475.
186. Palmer RH, Frank WO, Karlstadt R: **Maintenance therapy of duodenal ulcer with H2-receptor antagonists--a meta-analysis.** *Alimentary pharmacology & therapeutics* 1990, **4**(3):283-294.
187. Pendopharm Division of Pharmascience Inc: **Metonia (metoclopramide).** In: *CA Product Monograph.* 2014.
188. Pendopharm Division of Pharmascience Inc: **Axid (nizatidine).** In: *CA Product Monograph.* Montréal, QC; 2014.
189. Peura DA, Kovacs TO, Metz DC, Siepmann N, Pilmer BL, Talley NJ: **Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.** *The American journal of medicine* 2004, **116**(11):740-748.
190. Pfizer Inc: **AXID AR (nizatidine).** In: *US Product Monograph.* Madison, NJ; 2019.
191. Phupong V, Hanprasertpong T: **Interventions for heartburn in pregnancy.** *The Cochrane database of systematic reviews* 2015(9):Cd011379.
192. Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P: **Proton pump inhibitors for functional dyspepsia.** *The Cochrane database of systematic reviews* 2017, **3**:Cd011194.

193. Quan C, Talley NJ: **Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs.** *The American journal of gastroenterology* 2002, **97**(12):2950-2961.
194. Rabeneck L, Soucek J, Wristers K, Menke T, Ambriz E, Huang I, Wray N: **A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia.** *The American journal of gastroenterology* 2002, **97**(12):3045-3051.
195. Raghunath AS, Hungin AP, Wooff D, Childs S: **Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis.** *Alimentary pharmacology & therapeutics* 2004, **20**(7):733-744.
196. Ranchet G: **Sucralfate in the treatment of gravid pyrosis.** *G Ital Obstet Ginecol* 1990, **12**:1-16.
197. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, Stanton DS: **Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens.** *Annals of internal medicine* 1995, **123**(5):344-350.
198. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG: **Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study.** *The American journal of gastroenterology* 1996, **91**(2):223-227.
199. Regier L, Schuster B: **Helicobacter pylori testing & eradication.** In: *RxFiles drug comparison charts*. Saskatoon, SK: Saskatoon Health Region; 2017.
200. Regier L, Jensen B: **Nausea & Vomiting: Symptom Management.** In: *RxFiles drug comparison charts*. Saskatoon, SK: Saskatoon Health Region; 2017.
201. Regula J, Butruk E, Dekkers CP, de Boer SY, Raps D, Simon L, Terjung A, Thomas KB, Luhmann R, Fischer R: **Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.** *The American journal of gastroenterology* 2006, **101**(8):1747-1755.
202. Reisfield DR: **Pyrosis and pregnancy.** *Current therapeutic research, clinical and experimental* 1971, **13**(11):680-684.
203. Rey JF, Legras B, Verdier A, Vicari F, Gorget C: **Comparative study of sucralfate versus cimetidine in the treatment of acute gastroduodenal ulcer. Randomized trial with 667 patients.** *The American journal of medicine* 1989, **86**(6A):116-121.
204. Richter JE, Sabesin SM, Kogut DG, Kerr RM, Wruble LD, Collen MJ: **Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic**

- gastroesophageal reflux disease.** *The American journal of gastroenterology* 1996, **91**(9):1766-1772.
205. Richter JE: **Review article: the management of heartburn in pregnancy.** *Alimentary pharmacology & therapeutics* 2005, **22**(9):749-757.
206. Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE: **A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.** *Alimentary pharmacology & therapeutics* 1995, **9**(1):25-31.
207. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J: **Prevention of NSAID-induced gastroduodenal ulcers.** *The Cochrane database of systematic reviews* 2002(4):Cd002296.
208. Sakurai K, Nagahara A, Inoue K, Akiyama J, Mabe K, Suzuki J, Habu Y, Araki A, Suzuki T, Satoh K *et al*: **Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).** *BMC Gastroenterol* 2012, **12**:42.
209. Salas M, Ward A, Caro J: **Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.** *BMC Gastroenterol* 2002, **2**:17.
210. Sanis Health Inc: **Famotidine.** In: *CA Product Monograph.* Dieppe, NB; 2014.
211. Sanis Health Inc: **Domperidone.** In: *CA Product Monograph.* Dieppe, NB; 2015.
212. Sanofi: **Roloids.** In: *US Product Information.* Chattanooga, TN; 2019.
213. Satoh K, Yoshino J, Akamatsu T, Itoh T, Kato M, Kamada T, Takagi A, Chiba T, Nomura S, Mizokami Y *et al*: **Evidence-based clinical practice guidelines for peptic ulcer disease 2015.** *Journal of gastroenterology* 2016, **51**(3):177-194.
214. Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Naucler E, Svedberg LE: **Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON).** *Heart (British Cardiac Society)* 2011, **97**(10):797-802.
215. Schuster B, Regier L, Jensen B: **Acid Suppression.** In: *RxFiles drug comparison charts.* Saskatoon, SK: Saskatoon Health Region; 2017.
216. Schuster B: **Acid Suppression Drugs: Evidence, Tips & Pearls.** In: *RxFiles drug comparison charts.* Saskatoon, SK: Saskatoon Health Region; 2017.
217. Servey J, Chang J: **Over-the-Counter Medications in Pregnancy.** *American family physician* 2014, **90**(8):548-555.

218. Shaffer EA: **Gastroesophageal Reflux Disease**. In: *Therapeutic Choices*. Edited by Jovaisas B. Ottawa, ON: Canadian Pharmacists Association 2018.
219. Shield MJ: **Interim results of a multicenter international comparison of misoprostol and cimetidine in the treatment of out-patients with benign gastric ulcers**. *Digestive diseases and sciences* 1985, **30**(11 Suppl):178S-184S.
220. Sifrim D, Castell D, Dent J, Kahrilas PJ: **Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux**. *Gut* 2004, **53**(7):1024-1031.
221. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: **Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial**. *Annals of internal medicine* 1995, **123**(4):241-249.
222. Simon B, Muller P: **Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients**. *Scand J Gastroenterol Suppl* 1994, **206**:25-28.
223. Sivem Pharmaceuticals ULC: **Domperidone**. In: *CA Product Monograph*. St Laurent, QC; 2015.
224. Sontag S, Graham DY, Belsito A, Weiss J, Farley A, Grunt R, Cohen N, Kinnear D, Davis W, Archambault A *et al*: **Cimetidine, cigarette smoking, and recurrence of duodenal ulcer**. *The New England journal of medicine* 1984, **311**(11):689-693.
225. Stupnicki T, Dietrich K, Gonzalez-Carro P, Straszak A, Terjung A, Thomas KB, Luhmann R, Fischer R: **Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients**. *Digestion* 2003, **68**(4):198-208.
226. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, Chan FK: **Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial**. *Annals of internal medicine* 2010, **152**(1):1-9.
227. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines**. *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.
228. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI: **Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs**. *The New England journal of medicine* 1996, **334**(22):1435-1439.

229. Taha AS, McCloskey C, Prasad R, Bezlyak V: **Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.** *Lancet (London, England)* 2009, **374**(9684):119-125.
230. Takeda Canada Inc: **Dexilant (dexlansoprazole).** In: *CA Product Monograph.* Oakville, ON; 2016.
231. Takeda Canada Inc: **Pantoloc (pantoprazole sodium).** In: *CA Product Monograph.* Oakville, ON; 2018.
232. Takeda Pharmaceuticals America Inc: **Dexilant (dexlansoprazole).** In: *US Product Monograph.* Deerfield, IL; 2018.
233. Takeda Pharmaceuticals America Inc: **Prevacid (lansoprazole).** In: *US Product Monograph.* Deerfield, IL; 2018.
234. Talley NJ, Vakil N: **Guidelines for the management of dyspepsia.** *The American journal of gastroenterology* 2005, **100.**
235. Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, Lacy BE, DiBaise JK, Prather CM, Abraham BP *et al*: **Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study.** *Gastroenterology* 2015, **149**(2):340-349.e342.
236. Tan VP, Cheung TK, Wong WM, Pang R, Wong BC: **Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study.** *World journal of gastroenterology* 2012, **18**(42):6127-6133.
237. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD: **Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.** *PloS one* 2013, **8**(4):e62162.
238. Targownik LE, Metge CJ, Leung S, Chateau DG: **The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.** *Gastroenterology* 2008, **134**(4):937-944.
239. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD: **Use of proton pump inhibitors and risk of osteoporosis-related fractures.** *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 2008, **179**(4):319-326.
240. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J: **Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding.** *The American journal of gastroenterology* 2009, **104**(6):1475-1482.

241. Targownik L: **Dyspepsia and Peptic Ulcer Disease**. In: *Therapeutic Choices*. Edited by Jovaisas B. Ottawa, ON: Canadian Pharmacists Association; 2017.
242. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJ, Whitaker HJ, Farrington CP, Card TR, West J: **Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?** *Alimentary pharmacology & therapeutics* 2005, **22**(3):175-181.
243. ten Wolde S, Dijkmans BA, Janssen M, Hermans J, Lamers CB: **High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs**. *Alimentary pharmacology & therapeutics* 1996, **10**(3):347-351.
244. Thomson AB, Barkun AN, Armstrong D, Chiba N, White RJ, Daniels S, Escobedo S, Chakraborty B, Sinclair P, Van Zanten SJ: **The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study**. *Alimentary pharmacology & therapeutics* 2003, **17**(12):1481-1491.
245. Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, Khan AR, Al Tannir M, Erwin PJ, Ibrahim T *et al*: **Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis**. *PloS one* 2012, **7**(12):e50836.
246. **Chronic Undiagnosed Dyspepsia in Adults**
[\[http://www.topalbertadoctors.org/download/353/dyspepsia_guideline.pdf\]](http://www.topalbertadoctors.org/download/353/dyspepsia_guideline.pdf)
247. **Treatment of Gastroesophageal reflux disease in adults**
[\[http://www.topalbertadoctors.org/download/359/gerd_guideline.pdf?_20170623151800\]](http://www.topalbertadoctors.org/download/359/gerd_guideline.pdf?_20170623151800)
248. Tran T, Lowry AM, El-Serag HB: **Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies**. *Alimentary pharmacology & therapeutics* 2007, **25**(2):143-153.
249. Tunis SR, Sheinhait IA, Schmid CH, Bishop DJ, Ross SD: **Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis**. *Clinical therapeutics* 1997, **19**(4):743-757.
250. University of Michigan Health System: **Gastroesophageal reflux disease (GERD). Guideline**. In. Ann Arbor, MI: University of Michigan; 2012 May.
251. Valeant Pharmaceuticals North America LLC: **Pepcid (famotidine)**. In: *US Product Monograph*. Bridgewater, NJ; 2016.

252. Valeant Pharmaceuticals North America LLC: **Pepcid (famotidine)**. In: *US Product Monograph*. Bridgewater, NJ; 2018.
253. Van de Mierop L, Rutgeerts L, Van den Langenberg B, Staessen A: **Oral domperidone in chronic postprandial dyspepsia**. *Digestion* 1979, **19**(4):244-250.
254. van Kerkhoven LA, Laheij RJ, Aparicio N, De Boer WA, Van den Hazel S, Tan AC, Wittteman BJ, Jansen JB: **Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial**. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2008, **6**(7):746-752; quiz 718.
255. van Pinxteren B, Numans ME, Bonis PA, Lau J: **Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease**. *The Cochrane database of systematic reviews* 2006(3):Cd002095.
256. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts JL: **Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis**. *Digestive diseases and sciences* 1988, **33**(5):523-529.
257. Vela MF, Tutuian R, Katz PO, Castell DO: **Baclofen decreases acid and non-acid postprandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH**. *Alimentary pharmacology & therapeutics* 2003, **17**(2):243-251.
258. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ: **Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis**. *The American journal of gastroenterology* 2001, **96**(3):689-696.
259. Veldhuyzen van Zanten SJ, Bradette M, Chiba N, Armstrong D, Barkun A, Flook N, Thomson A, Bursley F: **Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool**. *Canadian journal of gastroenterology = Journal canadien de gastroenterologie* 2005, **19**(5):285-303.
260. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, Escobedo S, Lee J, Sinclair P: **A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study**. *The American journal of gastroenterology* 2005, **100**(7):1477-1488.
261. Verdickt W, Moran C, Hantzschel H, Fraga AM, Stead H, Geis GS: **A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis**. *Scandinavian journal of rheumatology* 1992, **21**(2):85-91.

262. Vertical Pharmaceuticals LLC: **Conzip (tramadol ER)**. In: *US Product Monograph*. Bridgewater, NJ; 2018.
263. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A *et al*: **A comparison of five maintenance therapies for reflux esophagitis**. *The New England journal of medicine* 1995, **333**(17):1106-1110.
264. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, Karlberg J, Wong BC: **Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials**. *Clinical Gastroenterology and Hepatology* 2007, **5**(2):178-185.
265. Williams MP, Pounder RE: **Review article: the pharmacology of rabeprazole**. *Alimentary pharmacology & therapeutics* 1999, **13 Suppl 3**:3-10.
266. Wong WM, Wong BCY, Hung WK, Yee YK, Yip AWC, Szeto ML, Fung FMY, Tong TSM, Lai KC, Hu WHC *et al*: **Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients**. *Gut* 2002, **51**(4):502-506.
267. Wyeth Pharmaceuticals LLC: **Protonix (pantoprazole)**. In: *US Product Monograph*. Philadelphia, PA; 2018.
268. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ: **A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group**. *The New England journal of medicine* 1998, **338**(11):719-726.
269. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L *et al*: **Optimum duration of regimens for Helicobacter pylori eradication**. *The Cochrane database of systematic reviews* 2013(12):Cd008337.
270. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G: **Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis**. *Helicobacter* 2008, **13**(6):532-541.